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Abstract
Background: The transcriptional activity of Nuclear hormone Receptors (NRs) is regulated by interaction with
coactivator or corepressor proteins. Many of these cofactors have been shown to have a misregulated expression
or to show a subcellular mislocalization in cancer cell lines or primary tumors. Therefore they can be factors
involved in the process of oncogenesis.
Results: We describe a novel NR coregulator, TACC1, which belongs to the Transforming Acidic Coiled Coil (TACC)
family. The interaction of TACC1 with Thyroid Hormone Receptors (TR) and several other NRs has been shown in a
yeast two-hybrid screen and confirmed by GST pulldown, colocalization and co-immunoprecipitation experiments.
TACC1 interacts preferentially with unliganded NRs. In F9 cells, endogenous TACC1 localized in the chromatin-
enriched fraction of the nucleus and interacted with Retinoid Acid Receptors (RARa) in the nucleus. TACC1
depletion in the cell led to decreased RARa and TRa ligand-dependent transcriptional activity and to delocalization
of TR from the nucleus to the cytoplasm.
Conclusions: From these experimental studies we propose that TACC1 might be a scaffold protein building up a
transcriptional complex around the NRs we studied. This function of TACC1 might account for its involvement in
several forms of tumour development.
Background
Nuclear hormone receptors (NRs) constitute a large
family, including receptors for retinoids, thyroid (TR)
and steroid hormones. They modulate transcription by
binding to their respective target along with many regu-
latory cofactors. NRs repress transcription on positive
promoters by binding corepressors, the best known of
which are N-CoR and SMRT [1,2]. Histone Deacetylases
(HDACs) are recruited and activated in this repressive
complex, which then inactivates chromatin, thereby
reducing transcription to below basal levels. Ligand
binding leads to an exchange between corepressors and
coactivators [3,4]. Several proteins bind to this primitive
core complex by building interaction networks that
eventually lead to activation of the chromatin by histone
acetylation. Interactions with basal transcription factors
eventually activate RNA polymerase, but similar interac-
tions also play a role during repression.
In mammals, TACC1 belongs, with TACC2 and
TACC3, to the Transforming Acidic Coiled-Coil family.
TACC proteins share a 200 amino acids C-terminal
conserved coiled-coil domain (CC domain), but diverge
in their N-terminal part. Many protein variants are
derived from each of these three genes [5]. Human
TACC genes were initially described as potential cancer
genes and are all present in genomic regions that are
rearranged in certain cancer cells [6-8], TACC1 having
been first discovered as the product of an amplicon in
breast cancer [7]. It was shown afterwards that its
expression was modified in several cancers [9-15]. The
first function for TACC proteins, which was subse-
quently well documented, lies at the level of the centro-
some, where they play a role in stabilizing microtubules
during formation of the mitotic spindle at mitosis
[16-18]. This function is presumably a factor involved in
cell transformation [19]. Other roles for TACC proteins
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translation [20] and in mRNA maturation [9]. A func-
tion for TACC proteins in transcriptional regulation was
first recognized for TACC3, which was described as an
interaction partner and a regulator for a transcription
cofactor, ARNT [21]. Since then, several studies have
described interactions between a transcription cofactor,
a protein belonging to a chromatin remodeling complex
or RXRb and one or several TACC proteins [5,22-25].
Subsequent studies showed that TACC3 can control
hematopoeitic cell differentiation through interaction
with the transcription coregulator FOG-1 [26] and can
relieve transcriptional repression on methylated promo-
ters via an association with the methyl binding protein
MBD2 [27]. This raises the possibility that the aberrant
expression of one or more TACC proteins may affect
gene regulation through their interaction with transcrip-
tional cofactors and components of chromatin remodel-
ing complexes, thus contributing to the oncogenic
processes described above.
In this study, we looked for the putative protein part-
ners of TRa through a yeast two-hybrid assay. We iden-
tified TACC1 as one such partner and also found that
TACC1 is able to bind to several unliganded NRs.
Through a functional assay using siRNA to down-regu-
late TACC1 in animal cells we concluded that TACC1
participates in the overall regulatory function of TR and
RAR on target gene expression. Moreover, we demon-
strated that TACC1 can control TR and RAR subcellu-
lar localization. Our findings provide, for the first time,
a general role for TACC1 as a cofactor in the transcrip-
tional regulation of several NRs.
Results
A mouse full-length TRa2 cDNA was used as a bait to
screen a mouse cDNA library. Twenty five clones show-
ing interaction with TRa2 were obtained. Sequencing
revealed that they belong to eight different cDNA
families. Six clones represented three different cDNAs
encoding different lengths of the C-terminal region of
the protein N-CoR. This result demonstrated that TRa2
interacts with the NR corepressor in yeast whereas we
(data not shown) and others [28] observed that this was
not the case in mammalian cells. One cDNA that gave
an interaction was the clone Y11, which encoded part of
the TACC1 protein (Fig 1).
TACC1 interacts with several Nuclear Receptors
We observed in a GST-pulldown assay that TRa2 signif-
icantly interacted with the shortest human TACC1-J iso-
form, whereas interaction with TRa1a p p e a r e dm u c h
weaker (Fig. 2A).
We observed that this interaction between the natural
TACC1-J protein and both TRa2a n dT R a1i s o f o r m s
also occurred in a yeast two-hybrid assay (see Additional
file 1). In these cells the interaction between TACC1
and TRa1 decreased when treated with T3. To check
for interactions between TACC1 products and TR iso-
forms in mammalian cells, we performed co-immuno-
precipitation assays in COS-7 cells co-transfected with
either TACC1-K or -J cDNAs and either TRa1, TRa2
or TRb1 cDNAs. Clear interactions between TACC1-K
and -J proteins and TR proteins were revealed (Fig 2B
and 3A). The presence of the ligand T3 significantly
decreased the interaction with TRa1a n dT R b1b u t ,a s
expected, had no effect on the interaction with TRa2
(Fig 2B). Helix 12 is known to participate in corepressor
dismissal when T3 binds to TRa1 [29]. Indeed helix 12
deletion impeded T3 from releasing TACC1-J from
TRa1 (Fig 2C). Further experiments indicate that
TACC1 amino acids (AA) 609 (Leu) and 610 (Ile)
(hTACC1 full-length protein numbering) were essential
for interaction with TRa1a n dT R a2 in yeast (data not
shown). They also appeared to determine strongly or
weakly the interaction in mammalian cells for both TRs
(Fig 3A).
Figure 1 Representation of hTACC1 isoforms (A, J, K, S and the
peptide Y11). Numbering represents the amino acid positions on
the seminal human TACC1-A protein [7]. Each number points to the
first amino acid of the following domain. The hatched region is the
coiled-coil domain (202 Amino Acids (AA), from AA 604 to AA 805).
For the nomenclature and schemes of the different isoforms, see
[9,13]. TACC1-K, -S and J proteins are natural variants. Compared to
TACC1-A, TACC1-K protein is a novel isoform that lacks the exon 5
C-terminal domain; exon 5 in the mature mRNA is 121 bases long
(see the sequence in TACC1-G, Genbank accession # BC041391). This
short exon 5 appeared erroneously as a short exon 6 in TACC1-G
and -J on Figure 6 in Lauffart et al. [31] (Ivan Still, pers. comm., with
permission). The TACC1-S protein lacks domains corresponding to
exons 2 and 3. The TACC1-J protein lacks the exon 2 and 3
domains and has the short exon 5 domain [31]. We found all four
TACC1’s in activated human RAJI cells; we found only TACC1-K and
-J in mouse cells. TACC1-Y11 is the peptide found to interact with
TRa2 in the yeast two-hybrid screen. Its mRNA contained the
coding sequence of the C-terminal domain of the TACC1 protein,
plus part of the 3’UTR sequence. The peptide begins at AA 491 and
ends at AA 805. So the Y11 peptide (286 AA) corresponds mainly to
the TACC1 coiled-coil domain. AA 525 to 553, corresponding to the
C-terminal part of exon 5, are missing in Y11.
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interact in a cellular environment we investigated the
localization of these products when expressed in trans-
fected COS-7. Cotransfection of TRa2a n dT A C C 1 - J
wild type (WT) or mutant (mut) showed that part of
TRa2 colocalized with wild type TACC1 (Fig 3B). The
mutation of AA 609 and 610 abolished the colocaliza-
tion. Similar results were obtained with HeLa cells (data
not shown).
Taken together, these results demonstrate that unli-
ganded TR proteins and TACC1 do interact in vitro and
in mammalian cells.
We tested interactions of TACC1-J through co-immu-
noprecipitation assays in COS-7 cells with several
nuclear receptors including RARa,R X R a,P P A R g,G R ,
and ERa in the absence or presence of their respective
ligands (see Additional file 2). All tested receptors
showed a clear interaction with TACC1 only in the
absence of their ligand. The reduction in interaction was
dependent on the dose of ligand as shown for RXR and
GR (see Additional file 2). Overexpressed GFP-TACC1-
A proteins displaced endogenous nuclear RARa (see
Additional file 3).
These data suggest that interaction with TACC1 in
mammalian cells is a shared property of several unli-
ganded nuclear receptors of both the steroid receptor
and TR families.
Endogenous TACC1 interacts with RARa in the nucleus
and is present in a nuclear chromatin-enriched fraction
We found that F9 embryonic carcinoma cells expressed
fairly high levels of endogenous TACC1. They appeared
to be the best cellular model to analyse in more detail
the intracellular localization of TACC1 and its interac-
tion with nuclear receptors. Cell fractionation revealed a
strong association between TACC1 and the nuclear pel-
let (Fig 4A). The nuclear interaction of TACC1 with a
nuclear receptor was thus explored in co-immunopreci-
pitation assays in F9 cells stably expressing a
Figure 2 Interaction of TACC1 and TRs in vitro, in yeast and in mammalian cells. (A) GST-pulldown assays were performed using in vitro
translated [
35S]-TRa1 (left) or [
35S]-TRa2 (right) incubated with GST-glutathione-Sepharose (lanes 2 and 4), or GST-hTACC1-J-glutathione-
Sepharose (lanes 3 and 5). Lanes 1 and 6 are [
35S]-TRa1o r[
35S]-TRa2 inputs (12.5%). (B, C) Flag-TACC1-J expression plasmid was cotransfected
into COS-7 cells with TRa1, TRa2, TRb1 (B) or TRa1 deleted from Helix12 expression plasmids (C), in the absence or presence of thyroid
hormone [T3 (10
-7M)]. Forty-eight hours after transfection, whole cell lysates were prepared and immunoprecipitated with anti TR antibody.
Immunoprecipitates were resolved by SDS-PAGE and blotted with anti-flag and anti-TR antibodies. Inputs correspond to 1% of the proteins used
for the coimmunoprecipitation assay.
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tein overexpression is only 5 fold compared to endogen-
ous RARa proteins (data not shown). The relative
amounts of Flag-RARa and TACC1 in the supernatant
versus the nuclear fraction were determined. As illu-
strated in Figure 4A, most TACC1 and RARa proteins
were found in the nuclear fraction of cell extracts. In
the co-immunoprecipitation assays we observed that
immunoprecipitation of the nuclear Flag-RARa brought
down the endogenous TACC1 protein. We conclude
from these results that, in F9 cells, endogenous TACC1
does interact with RARa within the nucleus.
The interaction of TACC1 with nuclear receptors
within the nucleus of the cell led us to speculate that
TACC1 might be a chromatin protein. To explore this
further we prepared cytosolic, soluble nuclear and chro-
matin-enriched fractions from F9 cells using a
sequential high salt extraction procedure. We observed
TACC1 to be localized in the chromatin-enriched frac-
tion (Fig 4B). To test the quality of the extraction proce-
dure, we checked the distribution of histone H3 and
RARa proteins in the two fractions (Fig 4B). As pre-
dicted, histone H3 was mainly found in the chromatin-
enriched fraction and RARa in both fractions. These
results suggest that TACC1-RARa interactions occur at
the level of the chromatin in the nuclear compartment.
TACC1 enhances Transcriptional activation by
TRa and RARa
We first tried to determine the function of TACC1 in a
functional assay. Interaction was assayed with a full-
length TRa1 and a CAT reporter gene under the con-
trol of a thyroid hormone response element, DR4, in
HeLa cells. Neither VP16 nor TACC1-Y11/VP16 alone
activated the reporter (data not shown). TRa1a l o n e
Figure 3 Interaction of TACC1 or mutant TACC1 and TR in mammalian cells.( A )F l a g - T A C C 1 - J ,F l a g - T A C C 1 - J m u t ,F l a g - T A C C 1 - Ko rF l a g -
TACC1-Kmut (mut refering to mutations L609A and I610A) expression plasmids were cotransfected with TRa1o rT R a2 expression plasmids into
COS-7 cells in the absence of T3 hormone. Forty-eight hours after transfection, whole cell lysates were prepared and immunoprecipitated with
anti-TR antibody. Immunoprecipitates were resolved by SDS-PAGE and blotted with anti-flag and anti-TR antibodies. Inputs correspond to 1% of
the proteins used for the coimmunoprecipitation assay. (B) Confocal microscopy analysis of the localization of co-transfected TRa2 and TACC1-K
(wt) or TACC1-K mutant (mut) in COS-7 cells.
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as predicted. Co-expression of the fusion protein
TACC1-Y11/VP16 repeatedly over-activated transcrip-
tion by 2.5 to 7 fold in many experiments, an effect
dependent on T3 (data not shown). These results
demonstrate that a functional interaction does occur
with TRa1 on the target DR4 in the presence of T3.
T h ep r e s e n c eo fV P 1 6i nt h ef u s i o np r o t e i np r e v e n t e d
us from reaching a conclusion on the function of Y11.
So we tried to investigate the role of TACC1 in regulat-
ing gene expression with TACC1 proteins devoid of
VP16. However, although we designed many TACC1
variants, every protein mostly stayed in the cytoplasm
when it was overexpressed.
We thus used an alternative strategy aimed at knock-
ing down endogenous expression of TACC1 in cells in
culture through RNA interference using a mixture of
four siRNAs designed from the human TACC1-J
sequences, in such a way that every TACC1-A, -K, -S, -J
mRNA and most of the other TACC1 mRNAs depicted
in Genbank and in the literature [30,31] should be tar-
geted. The siRNAs against human TACC1 were trans-
fected into HEK-293F cells or simian COS-7 cells. We
verified that they were completely or severely depleted
in the mRNAs for TACC1 but not for TACC2 and
TACC3 mRNA (see Additional file 4). Long TACC1
proteins (A and K) were totally absent (Fig 5A). It was
not possible to test the absence of the shortest proteins
(S and J) with the antibody used.
We then tested, in the treated HEK-293F cells, the
response of a reporter gene to activation by T3. The
cells were co-transfected with a TR-expression plasmid
and a luciferase reporter construct driven by a chicken
E6 lysozyme Thyroid hormone Responsive Element
(E6-TRELuc). In control HEK-293F cells treated with a
non-targeting siRNA, reporter expression was activated
by T3. In contrast, in TACC1 siRNA treated HEK-293F
cells, activation by T3 was decreased by 46% (Fig 5B). In
COS-7 cells activation by T3 was even more severely
decreased (data not shown). We also analysed in HEK-
293F cells the transcriptional activity of endogenous
RAR in response to all-trans retinoic acid (ATRA) on a
transfected luciferase reporter construct driven by a
Retinoic Acid Response Element (RARE). Activation of
the reporter expression was decreased by 50% in cells
treated with TACC1 siRNAs (Fig 5C). As controls we
checked the effects of siRNA on transcription induced
by the Oct4 (Fig 5D) and AP1 (Fig 5E) transcription fac-
t o r s .A ss h o w ni nF i g s .5 Da n d5 E ,d o w n - r e g u l a t i n g
TACC1 in the HEK-293F cells affected transactivation
by these factors to a less extent. Therefore the effects of
T A C C 1s i R N Aw e r er a t h e rm o r es p e c i f i ct ot r a n s c r i p -
tion by nuclear receptors.
To further investigate the role of TACC1 on the
expression of endogenous genes under more physiologi-
cal conditions, we analysed the regulation of expression
of endogenous retinoic acid-target genes in COS-7 cells.
The genes laminin B1, RARb and Hoxa1 are known to
be directly regulated by all-trans RA through RAR
[32-34]. We monitored their expression for 48 hours
following ATRA stimulation, after two days of siRNA
treatment. They showed a reduced activation by ATRA
in TACC1-deprived cells, the extent of reduction being
dependent on the gene and the time of the kinetics
(Fig 6).
We checked that in the conditions of experiments
depicted on Figures 5 and 6 the levels of TR and RAR
mRNAs were not decreased (data not shown). This
Figure 4 TACC1 interacts with RARa in the nucleus of F9 cells and is present in a nuclear chromatin-enriched fraction. (A) Cells from an
F9 cell line stably expressing Flag-RARa were fractionated into cytoplasmic (C) and nuclear (N) fractions. 800 μg of total protein of each fraction
were immunoprecipitated with an anti-Flag antibody. Immunoprecipitates were resolved by SDS-PAGE and blotted with anti-Flag or anti-
TACC1antibodies, which reveal only the longest TACC1 proteins (A and K). Absence of cross contamination between cytosolic and nuclear
fractions was verified using respectively anti-b-tubulin and anti-Histone H3 antibodies. The same amount of protein was loaded in each lane. (B)
F9 cells were fractionated into cytosolic (lane 1), soluble nuclear (lane 2) and chromatin-enriched (lane 3) fractions. Cell-equivalent amounts of
fractions were probed by immunoblotting with anti-TACC1, anti-RARa, and anti-Histone H3 antibodies.
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Page 5 of 13Figure 5 TACC1 participates to the modulation of transcriptional activity by nuclear receptors. (A) The protein levels of TACC1 in control
(non-targeting siRNA) or TACC1 siRNA treated cells were determined by immunoblotting with an anti-TACC1 antibody (Upstate). b-tubulin was
used as a loading control. (B, C, D, E) Non-targeting siRNA or TACC1 siRNA treated HEK-293F cells were transiently transfected with TRE-TKLuc
and TRa1 cDNA expression vector (B), RARE-TKLuc (C), Oct4-Binding Domain-Luc and Oct4 and Sox2 expression plasmids (D) or 5xcoll TATA Luc
(E). Cells were treated with 10
-7M of T3 (B) or all-trans RA (ATRA) (C) for 48 h. Firefly luciferase was normalized for cotransfected Renilla luciferase
activity (RLU). Open histogram, control siRNA treated cells; black histogram, TACC1 siRNA treated cells. The bars indicate the mean ± S.E. of
triplicate transfections from a representative experiment (* p < 0.05, ** p < 0.01, by Student’s-test).
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TACC1 knockdown.
Taken together, these data show that decreases in the
level of expression of TACC1 closely correlate with the
decrease in regulating activity of TR and RAR on nat-
ural target genes and thereby demonstrate that TACC1
is directly involved in the control of gene expression by
several NRs.
Interaction with TACC1 changes the intracellular
localizations of TR
To further address the question of how TACC1 acts on
TR function, we analysed whether the suppression of
endogenous TACC1 protein by transfecting HEK-293F
cells with siRNAs would alter the intracellular distribu-
tion of TR. We analysed the distribution of the fusion
protein made from a GFP-TRa1 construct in control
and TACC1 siRNA treated cells. As shown in Fig 7A, in
control cells the GFP-TRa1 signal was localized exclu-
sively within the nucleus independently of the intensity
of the fluorescence. In contrast, in TACC1-deprived
cells, the GFP-TRa1 protein was partly located in the
perinuclear cytoplasm in a significant proportion of the
TR-expressing cells (Fig 7B). The TACC1 protein might
therefore be involved in TR mobilisation within the
nucleus. Some results suggest that it would be the same
for endogenous RARa proteins.
Discussion
The TACC1 protein and other members of the TACC
protein family are known to be associated with the
Figure 6 TACC1 contributes to all-trans RA activation of RAR target genes. Induction by ATRA of three RAR target genes [RARb4 (A); Hoxa1
(B); Laminin B1 (C)] in non-targeting siRNA (open histogram) and TACC1 siRNA (black histogram) treated COS7 cells is measured by quantitative
RT-PCR. Cells were treated with siRNA for 48 h before being treated with ATRA (10
-7 M) for 48 h and the RNAs were extracted at different time
points. The constitutive gene 36b4 was used as a control. The error bars represent the SEM (* p = 0.08, ** p < 0.05, *** p < 0.01, by Student’s-
test).
Guyot et al. BMC Molecular Biology 2010, 11:3
http://www.biomedcentral.com/1471-2199/11/3
Page 7 of 13centrosomes and the mitotic spindle during mitosis
[10,16,35]. Other studies have shown that TACC pro-
teins are involved in mRNA translation (TACC3 or
Maskin) and could be associated with mRNA matura-
tion. We show in this study that TACC1 also plays a
role in the control of transcription by nuclear hormone
receptors and in the control of their nuclear localization.
TACC1 physically interacts with TRa1, TRa2 and TRb1
in yeast and mammalian cells as shown by several
experimental approaches. TACC1 also interacts with
RXRa,R A R a,P P A R g,E R a a n dG R( a n dA R ,p r e l i m i n -
ary results, not shown), transcription factors belonging
to the two nuclear receptor families. These interactions
involve only aporeceptors as ligand binding abolishes
the interaction. In the light of these results and other
reported interactions with transcription cofactors, it
would appear that TACC proteins play an important
role in transcriptional regulation.
Role of TACC1 in transcriptional control
Our present data clearly show that part if not all the
TACC1 protein within the nucleus is associated with
chromatin and that endogenous TACC1 interacts with
TR and RAR presumably within this chromatin bound
fraction.
A putative role for TACC1 in controlling transcription
by TR and RAR is suggested by the effects of knocking
down protein expression using siRNAs. In cells deprived
of TACC1 the ligand induced transcriptional activation
of TR and RAR target genes was strongly decreased.
This effect was observed on a transfected reporter gene,
as well as on endogenous cellular genes. This observa-
t i o nl e a d st ot h es u g g e s t i o nt h a tT A C C 1w o r k sa sa
coactivator. Similar conclusions were drawn for TACC2
which interacts with RXRb, on the lactoferrin promoter
[25].
T h e r e f o r eT A C C 1i sn e c e s s a r yf o rt h eo v e r a l lr e g u l a -
tory activity of TRs, RARa (our results), RXRb [25] and
presumably the other NRs we studied on target gene
expression, but its function might be complex. What
might be the mechanism of action of TACC1 as regards
nuclear receptors? It has been shown that TACC pro-
teins are able to physically interact with coactivators
GCN5, pCAF and CBP/p300, and with the chromatin
remodelers and regulators GAS41, INI-1 and MBD2.
TACC3 can be recruited by the latter on methylated
promoters and TACC3/MBD2 may form a complex
with HAT and reactivate transcription from methylated
genes [22,23,27]. GCN5 also binds to TR [36]. To
explain how TACC1 could act as a coactivator in the
presence of T3, despite the fact it no longer interacts
with TR, a coactivator (such as GCN5) could be pro-
posed as a bridge between TACC1 and TRs, permitting
a functional interaction without physical interaction.
This can explain why we observed a functional interac-
tion in the presence of T3, as demonstrated by the effect
of TACC1-Y11/VP16 on TRa1o naT R E .As i m i l a r
behaviour has been described for other transcription
cofactors such as Rap46 and PGC-2 [37]. After coactiva-
tor binding on TACC1, this protein could participate in
chromatin remodelling, for example, via the INI-1 com-
plex. However, TACC1 could be an activator in one
context and a repressor in another, as shown, for exam-
ple, for several coregulators such as Zac1 [38]. Although
our RNA interference results focus on its role in activa-
tion, we cannot exclude the possibility that it plays a
role in the repression complex on positive response ele-
ments because, in the absence of ligands, TACC1 physi-
cally interacts with several NRs including RXR, the
common partner to all non-steroid receptors. An inter-
action between TACCs and RXRb in the absence of
ligand has also been observed [5,25]. TACC1 interac-
tions with both partners on TREs or RAREs could con-
tribute to building the corepressor complex. Heldring et
al. proposed that N-CoR and SMRT would be recruited
to ERa via indirect mechanisms that require additional
Figure 7 Interaction with TACC1 changes TR intracellular
localization. The GFP-TRa1 construct was transfected into non-
targeting siRNA (A) or TACC1 siRNA (B) treated HEK-293F cells. The
distribution of GFP-TRa1 was analysed by confocal microscopy. The
cell nuclei were stained with DRAQ5 (red colour). Two
representative pictures are shown for each condition. We never
observed the GFP fluorescence in the cytoplasm of the control cells.
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remains to be determined if TACC1 interacts with core-
pressors or HDACs. Moreover, the siRNAs used were
designed to destroy mRNAs of TACC1-A, -K, -S and -J
variants, but they could also knock down most mRNA
isoforms present in the cells. The effect we observed on
TRa1 transcription resulted from the absence of
TACC1-A and K proteins, but presumably of many
other proteins such as TACC1-S and -J, which the anti-
body used could not reveal. We cannot exclude the pos-
sibility that one of the other isoforms could be a true
corepressor. For comparison, N-CoR is a paradigm for
corepressors but its natural splice variant N-CoRi is a
potent coactivator for unliganded TR [40]. These results,
taken as a whole, lead to the suggestion that TACC1 has
a dual function and that it is a scaffold protein that
organises transcription in NR-complexes. The same con-
clusion was independently reached by Vettaikkoruma-
kankauv et al [25].
One important observation was that, in TACC1
deprived cells, TRa1a n dp r e s u m a b l yR A R a were delo-
calized from the nucleus to the perinuclear cytoplasm.
This suggests that TACC1 is directly involved in con-
trolling the nuclear localization of both NRs or in regu-
lating the trafficking of these NRs within the chromatin
and thereby their availability to target genes. Thus the
reduced transcriptional activity mediated by these NRs
in TACC1-deprived cells mightp a r t l yr e s u l tf r o mt h i s
nuclear delocalization. Its importance would depend on
the balance between what is displaced in the cytoplasm
and what remains in the nucleus. The converse situation
is that overexpressed TACC1 can displace endogenous
RAR from the nucleus, presumably by interaction in the
cytoplasm, as shown by colocalization experiments with
TR. Similarly, overexpressed AINT (TACC3) displaced
the endogenous nuclear transcription cofactor ARNT
[21] and overexpressed TACC1 modulates a transcrip-
tional response of c-fos and c-jun genes [41]. All these
results suggest that some TACC1 action on transcrip-
tion modulation is indirect and takes place from the
cytoplasm. It could occur in pathological situations
when TACC1 is abnormally present in the cytoplasm or
depleted [9-12] in the cell, or under normal situations,
as described for TACC3. It maintains the coregulator
FOG-1 in the cytoplasm during the undifferentiated
state of hematopoietic cells, the terminal differentiation
occurring when TACC3 expression is weak, allowing
FOG-1 to activate the transcription factor GATA-1 [26].
TACC1 as a multifunctional protein and a transforming
protein
TACC1 appears to be a multifunctional protein similar
to many other coregulators [3]. It could work as a scaf-
fold protein organizing different functions around itself.
In particular it plays a role in building a structure, the
centrosome, and in controlling a function, transcription.
Am o d e lf o rs u c hp r o t e i n si sb-catenin, which forms
part of adherens junctions and is a transcription cofac-
tor for TCF/LEF. It has been recently demonstrated that
G-actin, a cytoskeleton component when polymerized,
regulates gene expression and participates in chromatin
remodelling [42]. This sheds light on how the cell can
coordinate morphology and transcription. TACC1 might
behave in a similar manner, coordinating transcriptional
control by several NRs, as well as mitosis.
TACC proteins are involved in several cancers such as
mammary, ovarian and gastric cancers, and in leukemia.
However their role as oncogenes [7,43] or tumour sup-
pressors [44] has not yet been clarified, as TACC pro-
teins are over- or underexpressed, depending on the
tumour cell lines and primary tumours [9-15,45]. There-
fore mutations in the structure and function of TACC1
in tumours could mislocalize the protein in a cell sub-
compartment or deplete one of them. The discovery of
TACC interactions with several NRs and previous
descriptions of interactions with transcription cofactors
has led to the assumption that pathological alterations
in the level of expression of TACC1 or in its localization
could directly and indirectly affect transcriptional regu-
lation of these NR target genes. For example, it has
been described that in the normal human prostate tissue
TACC1 is located in the nucleus [31] whereas it is cyto-
p l a s m i ci np r o s t a t ea d e n o c a r c i n o m a s[ 1 1 ] .I tc o u l d
thereby contribute to oncogenic development, as
described for other transcription coregulators [3,46]. It
is worth noting that alterations in TACC1 have been
found in breast cancers, a type of tumour whose devel-
opment is known to be controlled by estrogen receptors.
The initial description of TACC1 comes from the study
of an amplicon associated with ER-positive lobular carci-
nomas that metastasize to axillary lymph nodes [7]. If
amplification in 8p11 is associated with an overexpres-
sion of the TACC1 protein, our results suggest that this
could perturb the transcription of ER target genes, with
consequences for tumorigenesis or the metastasis pro-
cess. It is interesting that TACC1 has been recognized
as the strongest prognostic marker associated with
endocrine therapy resistance in breast tumours [45].
Conclusions
TACC proteins are well-known actors for the mitotic
spindle stabilization and the centrosome function [16].
Their role in transcription control is far less documen-
ted. Focusing on some Nuclear Hormone Receptors
(NRs), we show for the first time that TACC1 plays a
role in transcription. The mechanism appears complex
as TACC1 behaves as a coactivator since its absence
precludes full activation of Thyroid Hormone T3 and
retinoic acid-dependent promoters, while the interaction
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absence of their respective ligands. Overexpression and
underexpression have consequences on the subcellular
localization of TR and RAR. By its dual function, build-
ing the mitotic spindle and regulating transcription,
TACC1 might play a role in coordinating the mitosis
and transcription. The transforming properties of this
protein when misexpressed or mislocalized might be
due not only to defects of the spindle but also directly
from action on transcription.
Methods
Antibodies
The following antibodies were used: mouse monoclonal
antibody (mAb) anti-TRa1/b1 (C-1), rabbit polyclonal
antibodies anti GR (H-300), ERa(H-20), RXRa(D-20),
RARa(C-20), PPARg(H-100) (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA); rabbit polyclonal antibody anti-
TACC1 (Upstate cat # 07-229); mAb anti-Flag M2 and
mAb anti-Flag M2 HRP (Sigma); anti rabbit and anti
mouse IgG Horseradish peroxidase (HRP) conjugate
(Promega); anti rabbit and anti mouse Cy3-conjugated
IgG and anti rabbit fluorescein (FITC)-conjugated IgG
(Jackson) and mouse and rabbit Trueblot (eBioscience).
Yeast two-hybrid screen
Experiments were performed according to the Clontech
Laboratories protocols: manual PT3061-1, for the
Matchmaker two-hybrid system 2 in yeast (catalog #
K1604-1), and handbook PT3024-1 for the yeast proto-
cols. The full length TRa2 to be used as bait was cloned
from a cDNA library built from 17-day mouse embryos
(Clontech ML4006AB) to be used as bait. TRa2 is a nat-
ural variant form of the thyroid hormone receptor
encoded by the TR gene that is unable to bind the
ligand T3, in contrast to the receptor TRa1. TRa2w a s
fused downstream to the GAL4-DBD in pAS2-1. Yeast
cells, strains CG1945 and Y190, were transfected in par-
allel with the plasmid pAS2-1- TRa2 and were selected
i nt h ep r e s e n c eo f1m Mo r2 0m M3 - A T( a m i n o t r i a -
zole), respectively on an SD/-Trp medium. Yeast strains
expressing the TRa2-GAL4 DBD were then transfected
with a prey cDNA library constructed from 17-day
mouse embryo cDNA fused to GAL4-AD in the
pGAD10 vector. Transfected clones were selected on an
SD/-Trp/-Leu/-His/+3-AT medium (1 mM or 20 mM
depending on the strain, see above).
GST pulldown assay
The GST-TACC1-J fusion construct cloned into
the pGEX-3X plasmid were produced in bacteria upon
induction with 0.2 mM IPTG at 37°C. The bacteria were
sonicated, the lysate was centrifuged and the superna-
tant incubated with glutathione-Sepharose 4B beads
(Pharmacia) for 1 h at 4°C in PBS/0.1 mM PMSF/1%
Triton buffer. Beads were washed and protein
interactions were performed with [35S]-Met labelled
TRa synthesised in vitro using TNT kits (Promega).
The Sepharose beads were subsequently washed three
times with the PBS/PMSF/Triton buffer. Bound proteins
were eluted with loading buffer at 100°C and analysed
by SDS-PAGE and fluorography (Amplify, Amersham).
Plasmids and constructs
Human TACC1 cDNAs were amplified from a cDNA
library of activated RAJI cells by PCR with the following
primers: forward 5’-AGATCTGAATTCCATGGCGTT-
CAGCCCGTGGC-3’,r e v e r s e5 ’-AGATCTGAATTCT-
CAGTCAGTCTTTCCCAGC-3’. The four PCR products
were subcloned into the pGEM-T vector (Promega,
Madison, Wis.) and sequenced. The human TACC1
cDNAs (TACC1-A,-K,-S, and -J) were then cloned into
the BglII site of pSG5-Flag vector or pEGFP-C1.
Point mutations (TACC1 amino acids (AA) 609 (Leu)
and 610 (Ile) (hTACC1 full-length protein numbering)
were introduced using the commercial QuikChange
Site-Directed Mutagenesis kit according to the manufac-
turer’s protocol (Stratagene).
The pSG5 rat TRb1a n dp S G 5m o u s eT R a1c o n -
structs were gifts from ML. Privalsky. The pSG5 rat
TRa2 was provided by MA. Lazar. The pGL3 human
ERa (hERa), and pSG5 mouse PPARg constructs were
g i f t sf r o mV .L a u d e t .p S G 5G Rw a sg i f tf r o mJ M .
Vanacker. PSG5 mouse RXRa and RARa were gifts
from H. Escriva. The luciferase reporters used in trans-
fection experiments contain chicken E6 lysozyme Thyr-
oid hormone Responsive Element (E6-TRE) from Lee
and Privalsky and Retinoic Acid Response Element
(RARE) from G. Benoit. Renilla Luciferase used for nor-
malization was from Promega.
Truncated form of TRa1 (TRa1 Δ helix12) was ampli-
fied by PCR using High Fidelity polymerase (Roche) and
oligonucleotides that introduce EcoRI sites on the 5’
and 3’ ends, followed by subcloning into the EcoRI site
of the pSG5 vector.
Cell culture
All media were purchased from Invitrogen (Invitrogen/
Gibco, Carlsbad, CA). HEK-293F, HeLa and COS-7 cells
were maintained in Dulbecco’s Modified Eagle’sM e d -
ium (DMEM) supplemented with 6% heat-inactivated
fetal bovine serum, glutamine (2 mM), penicillin/strep-
tomycin (1000 U/ml). F9 mouse embryonic carcinoma
cells were cultured on 0.1% gelatin-coated plates in the
medium described above but supplemented with MEM
sodium pyruvate (1 mM). Cells were maintained at 37°C
in the presence of 5% CO2. Whenever indicated, char-
coal-stripped fetal bovine Serum (Biochrom, AG) was
used and hormones were used at 10
-6Mo r1 0
-7M.
Indirect immunofluorescence microscopy
Cells were seeded overnight on coverslips onto a
24 -well plate and transfected or not with 0.5-1 μgo f
Guyot et al. BMC Molecular Biology 2010, 11:3
http://www.biomedcentral.com/1471-2199/11/3
Page 10 of 13DNA with Exgen500 (Fermentas protocol). 48 h after
transfection, cells were fixed for 15 min in 0.5% formal-
dehyde/1.5% glutaraldehyde diluted in PBS. After exten-
sive washing, cells were subsequently overlaid with the
appropriate antibody (Santa Cruz Biotechnologies, Santa
Cruz, CA) diluted in 5% normal goat serum in the pre-
s e n c eo f0 . 1 %T r i t o nX - 1 0 0f o r1ha tr o o mt e m p e r a -
ture. After washing, anti-mouse or rabbit Cy3 or FITC
conjugated secondary antibody (Jackson ImmunoRe-
search Laboratories) was added and the cell nuclei were
later counterstained with DAPI (4’, 6-diamidino-2-phe-
nylindole dihydrochloride hydrate) (Sigma), Propidium
Iodide or DRAQ5 (Biostatus limited). The coverslips
were mounted on microscopy slides with FluorSave
embedding medium (Calbiochem) and imaged on the
appropriate fluorescence microscope.
Co-immunoprecipitation
Cos-7 cells were transfected using lipofectamin accord-
ing to the manufacturer’s protocol (Invitrogen/Gibco,
Carlsbad, CA). Cotransfected cell lysates were pre-
cleared at 4°C for 2 h by adding 100 μlp r o t e i nG -
Sepharose bead slurry (50%) per ml (Amersham) or
anti-Flag M2 affinity gel (Sigma), and 800 μg were incu-
bated at 4 C for 2 h in the presence of the appropriate
antibody (2 μg) or of a non specific control antibody (2
μg). The lysates were then incubated overnight at 4°C
with 100 μl protein G-Sepharose (50% slurry) (Amer-
sham) or anti-Flag M2 affinity gel (Sigma). The Sephar-
ose was washed twice with RIPA buffer and three times
with the washing buffer (20 mM Tris pH 8, 150 mM
NaCl, 2 mM EDTA, 1% Triton ×100) and immobilized
proteins were eluted with 50 μl protein gel loading buf-
fer. Immunoprecipitation was followed by Western blot-
ting to detect bound proteins.
Western blot analysis
Proteins were separated by SDS-PAGE then transferred
to nitrocellulose membranes, which were incubated for
2 hours at room temperature with blocking buffer
[TBST (20 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1%
Tween 20) + 2% non-fat dry milk]. After extensive
washing with TBST, the blots were hybridized for 1
hour with primary antibodies followed by 1 hour incu-
bation at room temperature with HRP-conjugated sec-
ondary antibodies against mouse or rabbit IgG
(Promega, Madison, Wis.) or true-blot detection system
(eBioscience) accordingly. The proteins were detected
using SuperSignal® West Pico Chemiluminescent, as
recommended by the manufacturer (Pierce, Perbio) and
autoradiographed.
Subcellular fractionations
Total proteins were extracted 48 h after transfection in
RIPA buffer (50 mM Tris pH 8, 140 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 1% Triton ×100, 0.1% Na-deoxy-
cholate) supplemented with Protease Inhibitor Cocktail
(Complete, Roche). After homogenisation at 4°C for 20
min, samples were centrifuged at 10,000 × g for 15 min
at 4°C and the supernatant containing proteins frozen
and stored at -80°C. Nuclear and cytoplasmic proteins
were isolated using Chemicon’s Nuclear Extraction Kit
according to the manufacturer’s protocol.
For F9 subcellular fractionation, cells were collected in
ice cold 1 × PBS and re-suspended at 4 × 10
7 cells/ml
i nb u f f e rA( 1 0m MH E P E Sp H7 . 9 ,1 0m MK C l ,1 . 5
mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM dithio-
threitol, and protease inhibitor cocktail [Roche]). Triton
X-100 was added (0.1% final concentration), the cells
were incubated on ice for 8 min, and the nuclei (fraction
P1) were collected by centrifugation (5 min, 1,300 × g,
4°C). The supernatant (fraction S1) was clarified by
high-speed centrifugation (5 min, 20,000 × g, 4°C), and
the supernatant (fraction S2) collected. The P1 nuclei
were washed once in buffer A and lysed for 30 min in
buffer B [3 mM EDTA, 0.2 mM EGTA, 1 mM dithio-
threitol and protease inhibitor cocktail (Roche)]. Insolu-
ble chromatin (fraction P3) and soluble (fraction S3)
fractions were separated by centrifugation (5 min,
1,700 × g, 4°C). The P3 fraction was washed once with
buffer B and re-suspended in SDS-Laemmli buffer and
boiled for 10 min. Protein concentrations were deter-
mined by BCA protein assay (Interchim).
RNA interference
Synthetic double-strand siRNA specific for the human
TACC1-J coding region (Custom Smart Pool siRNA)
and the siRNA ON-TARGET plus siCONTROL non-
targeting siRNA n°1 were purchased from Dharmacon
(Perbio). The day before transfection, COS-7 and HEK-
293F cells were seeded at 5 × 10
4 and 1.5 × 10
5 cells/ml,
respectively. Cells were transfected with 50 nM of
siRNA, using Dharmafect 1 (Dharmacon, Perbio)
according to the manufacturer’s protocol.
Luciferase assay
For transactivation-reporter assays, cells were seeded
onto 24-well plates overnight and transfected with DNA
and Exgen500 according to the manufacturer’sp r o t o c o l
(Fermentas). Transfected cells in each well were lysed
and processed for a dual luciferase assay according to
the manufacturer’s protocol (Dual-Luciferase Reporter
Assay, Promega, Madison, Wis.). Luminescence was
determined with a luminometer (Veritas, Microplate
Luminometer, Turner Biosystems). Relative luciferase
activity (RLU) was calculated as the Firefly luciferase
activity normalized to Renilla luciferase activity from
cotransfected pRL-CMV-luc.
Quantitative RT-PCR
For quantitative analysis real-time quantitative PCR was
carried out using primers designed with the Primer 3
software and produced by MWG (see Additional file 5).
The Mx3000p Detection system (Stratagene) was used
Guyot et al. BMC Molecular Biology 2010, 11:3
http://www.biomedcentral.com/1471-2199/11/3
Page 11 of 13with QuantiTect SYBR Green PCR Master Mix (Qiagen)
for the detection of PCR products. The cycle threshold
was set at a level where the exponential increase in PCR
amplification was approximately equal between all
samples.
Additional file 1: TACC1 interacts with TRa1a n dT R a2 in yeast.T h e
interaction between TACC1-Y11 and TRa1o rT R a2 was analysed in a
yeast two-hybrid assay, in the absence or presence of the thyroid
hormone [T3 (10
-7M)]. Interaction was quantified by measuring the b-gal
units produced by the activated reporter.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-3-
S1.PDF]
Additional file 2: TACC1 interacts with both steroid and non-
steroid nuclear receptors. The Flag-TACC1-J expression plasmid was
cotransfected with RARa (A), PPARg(B), ERa(C), RXRa(D) or GR(E)
expression plasmids into COS-7 cells in the absence or presence of their
respective ligands at the indicated concentrations. 48 h after transfection,
whole cell lysates were prepared and immunoprecipitated with anti-RAR,
-RXR, -PPAR, -ER or -GR antibody. Immunoprecipitates were resolved by
SDS-PAGE and blotted with anti-flag antibody. Inputs correspond to 1%
of the proteins used for the coimmunoprecipitation assay.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-3-
S2.PDF]
Additional file 3: Interaction between overexpressed TACC1 and
endogenous RARa. Cos7 cells were transfected (C), or not, with GFP
TACC1-A and immunofluoresence was performed against endogenous
RARa(D, E). We observed the colocalization of overexpressed TACC1 with
endogenous RARa (G). It appeared also that overexpressed TACC1
delocalized RARa from the nucleus to the cytoplasm; in non transfected
cells RARa is nuclear (F), whereas it is mainly cytoplasmic in transfected
cells (G). Note that overexpressed TACC1 was mainly cytoplasmic,
surrounding the nucleus, forming a structure that certainly corresponds
to aggregates previously described by Gergely and collaborators [47]. A
and B are DAPI stainings.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-3-
S3.PDF]
Additional file 4: Decrease of TACC1 mRNA level using specific
targeted TACC1 siRNA. The efficiency of TACC1 siRNA (50 nM) versus
Non Targeting siRNA (NT) was verified by RT-PCR analysis in Cos-7 and
HEK-293F cells. All TACC1 isoforms were amplified and HPRT was used as
internal control gene (A). TACC1 siRNA specificity was verified by
amplification of TACC1 (white), TACC2 (grey) and TACC3 (black) by
quantitative RT-PCR in Cos-7 and HEK-293F cells. The results were
normalised with 36B4 as a control mRNA (B).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-3-
S4.PDF]
Additional file 5: A table of oligonucleotides. Oligonucleotides used
in the experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2199-11-3-
S5.PDF]
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